Biotech Stock Plummets 58% After Failed Lupus Drug Trial

Shares of a biotechnology company crashed following disappointing clinical trial results for a key lupus treatment, highlighting the high risks associated with late-stage drug development.

1 Sept, 17:23 — 1 Sept, 17:23

Post Share

Sources

Showing 1 of 1 sources

Barron'sHigh6h ago

A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It - barrons.com

A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It barrons.com

Read full article →

Biotech Stock Plummets 58% After Failed Lupus Drug Trial

Sources

A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It - barrons.com

Related Stories

Rising Oil Prices Drive Up Bond Yields and Trigger Equity Sell-Offs

Global Bond Sell-Off Drives Up Yields Amid Market Volatility

N1 and CNN Confirm Expiration of Broadcasting Partnership Agreement

U.S. Equity Markets See Midday Swings Led by Palo Alto Networks Activity